Collagen is the main structural protein in the extracellular matrix of various connective tissues in the body. It is a major component of connective tissue and is the most abundant protein in mammals, accounting for 25-35% of the total body protein content. Collagen is held together by amino acids to form a triple helix of elongated fibers called a collagen helix. It is found mainly in connective tissues such as cartilage, bone, tendons, ligaments and skin. Common types of collagen include bovine collagen (mainly from cows), pig collagen (extracted from pig skin, bone and connective tissue) and Marine collagen (made from fish-derived collagen polypeptides).
Collagen has many medical uses in the treatment of bone and skin complications. Due to its powerful skin repair function, it is widely used in dermatology, burn department, laser cosmetology department and other subjects, so it is also called medical grade bioactive collagen, referred to as medical active collagen, and occasionally referred to as medical collagen. Medical collagen can be used in vascular grafts, cartilage repair, wound care, bone grafts and diagnosis, and can also be used as haemostat material and tissue scaffold material. Studies have shown that collagen is the most common used for bone grafting, with the highest market share of 24.52% in 2020. Since bones form the structure of the body, it is vital that they maintain their strength even when injured. Collagen is used in bone grafts mainly because it has a triple helix structure, making it a very strong molecule. Its effect on bone is ideal because it does not compromise the structural integrity of bone. The triple helix structure of collagen prevents it from being broken down by enzymes and it allows cells to stick to each other, which is important for the proper assembly of the extracellular matrix.
Medical Collagen Market Status Analysis and Prospect Forecast
Our research data has shown that the total market value of medical collagen in Europe and the US was $361 million in 2015 and increased to $475 million in 2020, with a CAGR of 22.77% from 2015 to 2020. On this basis, we carry out a series of functional calculations and use scientific models to derive the data of the last five years. Finally, we forecast that the medical collagen market in Europe and the US will be worth $627 million by 2025.
The
regional market concentration of medical collagen is high. The US is the
largest market by revenue, ranking first in the medical collagen revenue market
from 2015 to 2020. Its market value grew from $190 million in 2015 to $246
million in 2020, accounting for 51.88% of the market, with a CAGR of 11.23%
between 2015 and 2020. As the world's largest developed economy, the US enjoys
political and social stability, a sound legal system, a sound market system and
rapid development. It is the north American leader in market volume,
technological prowess, educational innovation and labor productivity. In terms
of production, the US has developed various industries, with many local brands
and good market competition. In addition, Germany, France, Italy and the UK, ect.,
these European countries also occupy a certain market share. In 2020, Germany
ranked first in the European market with a market share of 11.37%, and became
the fastest growing market in Europe, with a good development trend.
In
2020, Integra Life Science ranked first in the Medical collagen market in
Europe and the United States with 38.97% market share. SDM Biomedical ranked
second with 17.96%; Collagen Matrix ranked the third with 9.48%. The top six
enterprises in Europe and the United States accounted for 79.32% of the whole
market.
Get the complete sample, please click:https://www.globalmarketmonitor.com/reports/762387-medical-collagen-market-report.html
Impact of Epidemic on Medical Collagen Market
The
impact of the epidemic on the medical collagen market will involve all major
links and entities in the industrial chain. Prevention and control measures
such as family isolation and the extension of the Lunar New Year holiday have
been adopted to avoid large-scale population movements and gatherings. More and
more cities are entering a level 1 response mode to strictly control the
movement of people and prevent the spread of the disease. This prevented
non-local staff from returning or arriving immediately, left insufficient staff
and disrupted normal commutes, leading to mass production stopovers. Road
closures and village closures in various regions have hindered the transport of
raw materials such as pork, pepsin and acetic acid, as well as salt products. Existing stocks of raw and auxiliary
materials may not be able to meet the needs of normal production, and most
companies cannot sustain production with raw material stocks. The operating
costs of medical collagen companies will be affected by the increased costs of
raw materials and logistics, the development of online shopping habits of
consumers and distributors, and the difficulty of recycling after the epidemic
has eased. In addition, consumers will have less demand for products due to
lower incomes, which further challenges business development. In addition, the
intensification of the epidemic has posed a severe challenge to the global
healthcare system. In a related report, the Center for Surgical Efficacy and
Patient Safety at Massachusetts General Hospital said the number of operations
canceled worldwide due to the epidemic will reach about 28.4 million by 2020. Most
of the cancellations were for non-cancer patients. The high number of
cancellations during the pandemic means that the demand for medical collagen in
healthcare facilities will also be greatly reduced in the short term.
Get the complete sample, please click:https://www.globalmarketmonitor.com/reports/762387-medical-collagen-market-report.html
We provide more professional and intelligent market reports to complement your business decisions.
Chinese